)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SomnoMed
SomnoMed (SOM) investor relations material
SomnoMed H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary28 Aug, 2026
Executive summary
FY26 revenue grew 3% to $114.5m, with EBITDA up 19% to $10.9m and margin improving to 9.6%, led by North America.
Manufacturing capacity expanded by over 20% in FY26, reducing production times by more than 50% over two years.
Virtus, a new oral appliance for OSA and bruxism, advanced through controlled global market release with positive early feedback.
Leadership transitioned to a single CEO structure, with new COO and CMO appointments, and a focus on strategic priorities.
Maintained robust net cash position of $16.8m at year-end.
Financial highlights
Revenue rose 3% to $114.5m, EBITDA increased 19% to $10.9m, and margin improved to 9.6%.
Gross profit grew 5% to $70.0m; group gross margin improved to 61.1%.
Operating cash flow after leases was $5.2m; capital expenditure totaled $5.7m, over half directed to growth and capacity.
Cash and cash equivalents at year-end were $17.2m, with net cash of $16.8m.
Debt reduced by 48% to $0.4m; free cash flow was -$0.6m, reflecting planned growth investments.
Outlook and guidance
Targeting high single-digit revenue growth and stable EBITDA margins in FY27.
FY27 guidance to be detailed at the AGM, pending further clarity on regional growth and FX impacts.
Strategic focus on organic growth, product innovation, Virtus rollout, and expanding market access.
Long-term goal to return to double-digit revenue growth and expand EBITDA margins.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SomnoMed
- Record revenue and EBITDA growth, positive cash flow, and FY26 guidance reaffirmed.SOM
H1 2026 - Double-digit revenue growth, operational gains, and FDA-cleared innovation drive strong outlook.SOMAGM 2025 Presentation
- Q1 FY26 revenue up 13.5%, Rest Assure® US clinical study and FDA protocol progress achieved.SOMQ1 2026 TU
- Strong FY25 growth and innovation in OAT position the company as a leader in OSA treatment.SOMInvestor Presentation
- Record revenue and EBITDA, positive cash flow, and FDA-cleared innovation drive robust growth.SOMH2 2025
- Q4 FY25 revenue surged 25.1% year-over-year, with FY25 results surpassing guidance.SOMQ4 2025 TU
- FY 2024 revenue up 9.6% to AUD 91.7M; FY 2025 targets AUD 100M revenue and EBITDA above AUD 5M.SOMH2 2024
- Revenue up 19%, EBITDA positive, and upgraded guidance reflect strong operational turnaround.SOMH1 2025
Next SomnoMed earnings date
H1 202725 Feb, 2027
SomnoMed
Next SomnoMed earnings date
H1 202725 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
SomnoMed Limited is an Australian-based medical device company, publicly listed on the Australian Stock Exchange, specializing in the development and manufacturing of oral devices for the treatment of obstructive sleep apnea (OSA) and other sleep-related disorders. The company's product portfolio includes a range of custom-made oral appliances such as the SomnoDent series (Avant, Classic, Flex, Fusion, Herbst Advance Elite, and Herbst Advance), SomMorning Repositioner, SomnoBrux, and SomTabs for cleaning oral appliances. The company is headquartered in Sydney, Australia, and its shares are listed on the Australian Stock Exchange.